Clinical Study
Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study
Table 1
Differences between groups.
| | Clozapine () | Other antipsychotics () | Test | < |
| Characteristics at the baseline | | | | | Age (M ± SD) | 38.48 ± 11.45 | 45.39 ± 12.16 | | 0.07 | Men (%) | 65.2 | 69.6 | | 0.50 | Diagnosis (%) | | | | 0.05 | Schizophrenia | 87.0 | 56.5 | | | Psychotic Disorder NOS | 13.0 | 43.5 | | | Age at onset (M ± SD) | 22.91 ± 6.88 | 26.22 ± 7.20 | | 0.05 | Years since diagnosis (M ± SD) | 15.17 ± 8.11 | 18.57 ± 10.74 | | 0.26 | Risperidone (%) | — | 19.6 | — | — | Olanzapine (%) | — | 19.6 | — | — | Quetiapine (%) | — | 6.5 | — | — | Aripiprazole (%) | — | 2.2 | — | — | Psychotic episodes ≥ 5 (%) | 43.5 | 30.4 | | 0.27 | Schizophrenia in the family members (%) | 13.0 | 26.1 | | 0.23 | PANSS positive symptoms at the baseline (M ± SD) | 22.87 ± 6.82 | 17.83 ± 6.83 | | 0.05 | PANSS negative symptoms at the baseline (M ± SD) | 30.65 ± 9.24 | 24.70 ± 9.72 | | 0.07 | PANSS general symptoms at the baseline (M ± SD) | 48.61 ± 13.10 | 44.96 ± 12.02 | | 0.34 | CDSS at the baseline (M ± SD) | 2.78 ± 4.02 | 4.50 ± 3.85 | | 0.05 | CDSS ≥ 5 (%) | 30.4 | 40.9 | | 0.34 | SUMD awareness (M ± SD) | 21.91 ± 11.24 | 16.95 ± 10.27 | | 0.10 | SUMD symptoms attribution (M ± SD) | 23.74 ± 11.14 | 17.05 ± 11.32 | | 0.054 | Characteristics at the follow-up | | | | | Clozapine doses (mg (range)) (M ± SD) | 410.87 ± 127.88 (200/750) | — | — | — | Years of treatment with the current antipsychotic (M ± SD) | 5.36 ± 5.31 | 4.70 ± 2.22 | | 0.66 | Suicidal ideation (%) | 26.1 | 21.7 | | 0.50 | Suicide attempts (%) | 13.0 | 17.4 | | 0.50 | Change from baseline in the PANSS positive symptoms (M ± SD) | −8.43 ± 8.88 | −6.70 ± 7.56 | | 0.24 | Change from baseline in the PANSS negative symptoms (M ± SD) | −4.78 ± 11.07 | −6.87 ± 10.57 |
231.00
| 0.46 | Change from baseline in the PANSS general symptoms (M ± SD) | −8.96 ± 17.23 | −13.39 ± 17.32 | | 0.47 | Change from baseline in the CDSS (M ± SD) | 0.48 ± 5.29 | −2.05 ± 4.50 | | 0.05 | CDSS response* (%) | 71.4 | 60.0 | | 0.52 | Change in the SUMD awareness (M ± SD) | −6.71 ± 6.85 | −7.92 ± 4.96 | | 0.29 | Change from baseline in the SUMD symptoms attribution (M ± SD) | −7.81 ± 7.41 | −6.62 ± 3.93 | | 0.97 |
|
|
had been defined as a 50% change of baseline scores for patients with a CDSS score of 5 and higher at the baseline.
|